Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-05-05

Terns Pharmaceuticals, Inc. (TERN)

CEO Amy Burroughs was paid $8,240,502 in fiscal year 2024 (SEC filing 0000950170-25-060138 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$8,240,502
Amy Burroughs total, FY2024
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Amy Burroughs$563,701$0$807,750$6,476,968$375,000$0$17,083$8,240,502
Chief Executive Officer and Director
Mark Vignola475,000810,417375,375528,120190,0000538,0252,916,937
Former Chief Financial Officer and Treasurer
Melita Sun Jung319,05120,00001,687,198166,00203,8332,196,084
Chief Business Officer
Erin Quirk232,544473,529409,500576,13100243,2591,934,963
Former President, Head of Research & Development

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Amy Burroughs$8,240,502———
Mark Vignola2,916,9373,137,032908,330↓ −220,095
Melita Sun Jung2,196,084———
Erin Quirk1,934,9634,665,8451,132,905↓ −2,730,882

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Terns Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TERN reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Terns Pharmaceuticals, Inc. Peer Teardown Report

$8,240,502 Amy Burroughs total, FY2024

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of May 5, 2026 · Source: 0000950170-25-060138 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for TERN

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
TERNon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order TERN

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against TERN
8 companies name TERN as a compensation peer

The list of companies that name TERN as a peer is temporarily unavailable — recheck shortly.

Get the Terns Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Amy BurroughsCEO$8,240,502
Erin QuirkExecutive$1,934,963
Mark VignolaCFO$2,916,937
Melita Sun JungChief Business Officer$2,196,084
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Ann TaylorFormer director (through FY2024)$200,962
Carl GordonFormer director (through FY2024)$192,268
David FellowsChair of the Board$234,829
Heather TurnerIndependent Director$249,800
Hongbo LuIndependent Director$197,966
Jeffrey KindlerIndependent Director$198,268
Jill QuigleyIndependent Director$300,457
Radhika TripuraneniIndependent Director$205,922
Robert AzelbyIndependent Director—
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Heather TurnerDirector2025-06-11A45,000$0$0Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Hongbo LuDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
David FellowsDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-13A5,000418,600CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-13A5,000418,750CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-16A5,000419,733CommonForm 4 ↗
Amy BurroughsDirector2025-06-25A23,314490,230CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-27A5,000419,650CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-27A5,000419,634CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2025-07-01D85343,640Common, open-market saleForm 4 ↗
Emil KuriakoseChief Medical Officer2025-10-01D94487,407Common, open-market saleForm 4 ↗
Jill QuigleyDirector2025-11-04D24,52000Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2025-11-04D24,52018441,360CommonForm 4 ↗
Jill QuigleyDirector2025-11-04A24,5209226,565CommonForm 4 ↗
Amy BurroughsDirector2026-01-02D21,55100Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-02D9553836,632Common, open-market saleForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-02D200407,920Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-02A21,551599,997CommonForm 4 ↗
Amy BurroughsDirector2026-01-05D150,00000Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-05D71,339382,718,230Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-05A150,000——CommonForm 4 ↗
Amy BurroughsDirector2026-01-14A150,00000CommonForm 4 ↗
Amy BurroughsDirector2026-01-14A300,00000Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-01-14A137,50000Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-01-14A68,75000CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-14A112,50000Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-14A56,25000CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D27,08300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D61,228372,266,373Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-15D27,08300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D14,58300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D7,52138282,230Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-15A14,583567,665CommonForm 4 ↗
Amy BurroughsDirector2026-01-15A27,0835125,665CommonForm 4 ↗
Amy BurroughsDirector2026-01-15A27,0835125,665CommonForm 4 ↗
David FellowsDirector2026-02-01A2,82800Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-02-01—8,485——5 insiders, 5 accrual rows
Amy BurroughsDirector2026-02-17D14,58300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-02-17D4,08340162,501Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-02-17D8,15939319,963Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-02-17D2,3413889,114Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-02-17A14,583567,665CommonForm 4 ↗
Amy BurroughsDirector2026-03-16A14,583567,665CommonForm 4 ↗
Amy BurroughsDirector2026-03-16D14,58300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-03-16D2,77047131,028Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-03-16D11,81347550,081Common, open-market saleForm 4 ↗
Emil KuriakoseChief Medical Officer2026-04-01D9425349,693Common, open-market saleForm 4 ↗
Jill QuigleyDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
Robert AzelbyDirector2026-05-05D90,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D8,31953440,907CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D146,614537,770,542CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D137,500——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D2,828——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D10,657——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D24,562531,301,786CommonForm 4 ↗
David FellowsDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D22,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D28,475——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D4,676——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D22,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D3,955——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D4,676——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-05-05D64,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D300,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D1,250,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D955,534——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D150,000537,950,000CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D750,000——Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D68,750533,643,750CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D40,503532,146,659CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D112,500——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D280,000——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D120,000——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D117,500——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D485,000——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D81,953534,343,509CommonForm 4 ↗
David FellowsDirector2026-05-05D22,000——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D28,475——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D8,183——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D18,650——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D10,657——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D10,657——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D64,000——Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Robert AzelbyDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 108 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Heather TurnerDirector2025-06-11A45,000$0$0Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Hongbo LuDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
David FellowsDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2025-06-11A45,00000Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-13A5,000418,600CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-13A5,000418,750CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-16A5,000419,733CommonForm 4 ↗
Amy BurroughsDirector2025-06-25A23,314490,230CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-27A5,000419,650CommonForm 4 ↗
Andrew GengosChief Financial Officer2025-06-27A5,000419,634CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2025-07-01D85343,640Common, open-market saleForm 4 ↗
Emil KuriakoseChief Medical Officer2025-10-01D94487,407Common, open-market saleForm 4 ↗
Jill QuigleyDirector2025-11-04D24,52000Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2025-11-04D24,52018441,360CommonForm 4 ↗
Jill QuigleyDirector2025-11-04A24,5209226,565CommonForm 4 ↗
Amy BurroughsDirector2026-01-02D21,55100Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-02D9553836,632Common, open-market saleForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-02D200407,920Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-02A21,551599,997CommonForm 4 ↗
Amy BurroughsDirector2026-01-05D150,00000Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-05D71,339382,718,230Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-05A150,000——CommonForm 4 ↗
Amy BurroughsDirector2026-01-14A150,00000CommonForm 4 ↗
Amy BurroughsDirector2026-01-14A300,00000Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-01-14A137,50000Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-01-14A68,75000CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-14A112,50000Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-01-14A56,25000CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D27,08300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D61,228372,266,373Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-15D27,08300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D14,58300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-01-15D7,52138282,230Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-01-15A14,583567,665CommonForm 4 ↗
Amy BurroughsDirector2026-01-15A27,0835125,665CommonForm 4 ↗
Amy BurroughsDirector2026-01-15A27,0835125,665CommonForm 4 ↗
David FellowsDirector2026-02-01A2,82800Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-02-01A1,69700Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-02-01A1,69700Derivative, Class A CommonForm 4 ↗
Robert AzelbyDirector2026-02-01A1,69700Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-02-01A1,69700Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-02-01A1,69700Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-02-17D14,58300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-02-17D4,08340162,501Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-02-17D8,15939319,963Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-02-17D2,3413889,114Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-02-17A14,583567,665CommonForm 4 ↗
Amy BurroughsDirector2026-03-16A14,583567,665CommonForm 4 ↗
Amy BurroughsDirector2026-03-16D14,58300Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-03-16D2,77047131,028Common, open-market saleForm 4 ↗
Amy BurroughsDirector2026-03-16D11,81347550,081Common, open-market saleForm 4 ↗
Emil KuriakoseChief Medical Officer2026-04-01D9425349,693Common, open-market saleForm 4 ↗
Jill QuigleyDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
Robert AzelbyDirector2026-05-05D90,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D8,31953440,907CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D146,614537,770,542CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D137,500——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D2,828——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D10,657——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D24,562531,301,786CommonForm 4 ↗
David FellowsDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D22,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D28,475——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D4,676——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D22,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D3,955——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D4,676——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-05-05D64,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D300,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D1,250,000——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D955,534——Derivative, Class A CommonForm 4 ↗
Amy BurroughsDirector2026-05-05D150,000537,950,000CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D750,000——Derivative, Class A CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D68,750533,643,750CommonForm 4 ↗
Andrew GengosChief Financial Officer2026-05-05D40,503532,146,659CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D112,500——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D280,000——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D120,000——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D117,500——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D485,000——Derivative, Class A CommonForm 4 ↗
Emil KuriakoseChief Medical Officer2026-05-05D81,953534,343,509CommonForm 4 ↗
David FellowsDirector2026-05-05D22,000——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D28,475——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D8,183——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D18,650——Derivative, Class A CommonForm 4 ↗
David FellowsDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Jeffrey KindlerDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Jill QuigleyDirector2026-05-05D10,657——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D32,000——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D10,657——Derivative, Class A CommonForm 4 ↗
Radhika TripuraneniDirector2026-05-05D64,000——Derivative, Class A CommonForm 4 ↗
Heather TurnerDirector2026-05-05D45,000——Derivative, Class A CommonForm 4 ↗
Robert AzelbyDirector2026-05-05D1,697——Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Erin QuirkOTHER—————$409,500
Mark VignolaOTHER—————375,375
Amy BurroughsOTHER—————807,750
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mark VignolaOption17,6055.36—
Mark VignolaOption187,5008.94—
Amy BurroughsOption1,250,0007.31—
Mark VignolaOption137,5005.46—
Amy BurroughsPSU150,000—831,000
Mark VignolaPSU68,750—380,875
Mark VignolaOption22,50010.72—
Melita Sun JungOption475,0005.08—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation program is designed to attract and retain talent, align executive interests with stockholders, and provide a fixed base salary reflecting skill and responsibility, supplemented by performance-based cash bonuses and long-term equity incentives.

CEO STI target (% of salary)50%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards
Clawback policytrue
Anti-hedgingfalse
Anti-pledgingfalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-11—————
20242024-06-10—————
20232023-06-12—————
20222022-06-16—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-11—a
20242024-06-10—b
20232023-06-12—c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jill QuigleyIndependent · Audit (Chair) · Nominating and Corporate Governance$51,229$0$147,585$0$101,643$300,457
Heather TurnerIndependent · Audit · Newly elected5,6790244,12100249,800
David FellowsIndependent · Board Chair · Compensation · Nominating and Corporate Governance51,0490183,78000234,829
Radhika TripuraneniIndependent · Audit · Research and Development (Chair)37,6540168,26800205,922
Ann TaylorIndependent · Not standing for re-election · Departed during FY32,6940168,26800200,962
Jeffrey KindlerIndependent · Compensation (Chair)30,0000168,26800198,268
Hongbo LuIndependent · Nominating and Corporate Governance · Research and Development29,6980168,26800197,966
Carl GordonIndependent · Not standing for re-election · Departed during FY24,0000168,26800192,268
Amy BurroughsEmployee director000—00
Robert AzelbyIndependent · Compensation · Newly elected000000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$262,003
Equity awards (grant-date value)$0
All other compensation$101,643
Total cost of the board$363,646

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Terns Pharmaceuticals, Inc.2024Amy Burroughs$563,701$807,750$6,476,968$375,000$8,240,502

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Terns Pharmaceuticals, Inc. in fiscal 2024?
As disclosed, Amy Burroughs (Chief Executive Officer and Director) was the highest-paid executive at Terns Pharmaceuticals, Inc. in fiscal 2024, with total compensation of $8,240,502.
How much does Terns Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Terns Pharmaceuticals, Inc. reported total board compensation of $363,646 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Amy BurroughsDEF 14A2025-04-290000950170-25-060138Section “Executive Compensation”. As printed: 8,240,502. Filing ↗machine: r3 · c29 · span 385759–385768
2Section 01, Mark VignolaDEF 14A2025-04-290000950170-25-060138Section “Executive Compensation”. As printed: 2,916,937. Filing ↗machine: r6 · c29 · span 416551–416560
3Section 01, Melita Sun JungDEF 14A2025-04-290000950170-25-060138Section “Executive Compensation”. As printed: 2,196,084. Filing ↗machine: r8 · c29 · span 437336–437345
4Section 01, Erin QuirkDEF 14A2025-04-290000950170-25-060138Section “Executive Compensation”. As printed: 1,934,963. Filing ↗machine: r4 · c29 · span 396035–396044
5Section 03, Erin Quirk OTHERDEF 14A2025-04-290000950170-25-060138Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t5 · r4 · c12 · span 390796–390803
6Section 03, Mark Vignola OTHERDEF 14A2025-04-290000950170-25-060138Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t5 · r6 · c12 · span 411439–411446
7Section 03, Amy Burroughs OTHERDEF 14A2025-04-290000950170-25-060138Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t5 · r3 · c12 · span 380457–380464
8Section 08, Jill QuigleyDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 300,457. Filing ↗machine: span 712605–712814
9Section 08, Heather TurnerDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 249,800. Filing ↗machine: span 730109–730318
10Section 08, David FellowsDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 234,829. Filing ↗machine: span 689258–689467
11Section 08, Radhika TripuraneniDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 205,922. Filing ↗machine: span 724340–724549
12Section 08, Ann TaylorDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 200,962. Filing ↗machine: span 718544–718753
13Section 08, Jeffrey KindlerDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 198,268. Filing ↗machine: span 700991–701200
14Section 08, Hongbo LuDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 197,966. Filing ↗machine: span 706770–706979
15Section 08, Carl GordonDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 192,268. Filing ↗machine: span 695207–695416
16Section 08, Amy BurroughsDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 0. Filing ↗
17Section 08, Robert AzelbyDEF 14A2025-04-290000950170-25-060138Section “Director Compensation”. As printed: 0. Filing ↗
18Section 02, Heather Turner 2025-06-11Form 42025-06-120001562180-25-004757Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Jeffrey Kindler 2025-06-11Form 42025-06-120001562180-25-004758Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Hongbo Lu 2025-06-11Form 42025-06-120001562180-25-004759Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Radhika Tripuraneni 2025-06-11Form 42025-06-120001562180-25-004760Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, David Fellows 2025-06-11Form 42025-06-120001562180-25-004755Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Jill Quigley 2025-06-11Form 42025-06-120001562180-25-004756Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Andrew Gengos 2025-06-13Form 42025-06-160001562180-25-004866Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Andrew Gengos 2025-06-13Form 42025-06-160001562180-25-004866Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Andrew Gengos 2025-06-16Form 42025-06-160001562180-25-004866Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Amy Burroughs 2025-06-25Form 42025-06-250001562180-25-005077Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Andrew Gengos 2025-06-27Form 42025-06-300001562180-25-005120Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Andrew Gengos 2025-06-27Form 42025-06-300001562180-25-005120Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Emil Kuriakose 2025-07-01Form 42025-07-030001562180-25-005308Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Emil Kuriakose 2025-10-01Form 42025-10-020001892413-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Jill Quigley 2025-11-04Form 42025-11-050001799780-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Jill Quigley 2025-11-04Form 42025-11-050001799780-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Jill Quigley 2025-11-04Form 42025-11-050001799780-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Amy Burroughs 2026-01-02Form 42026-01-060001872564-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Emil Kuriakose 2026-01-02Form 42026-01-060001892413-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Emil Kuriakose 2026-01-02Form 42026-01-060001892413-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Amy Burroughs 2026-01-02Form 42026-01-060001872564-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Amy Burroughs 2026-01-05Form 42026-01-060001872564-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Amy Burroughs 2026-01-05Form 42026-01-060001872564-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Amy Burroughs 2026-01-05Form 42026-01-060001872564-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Amy Burroughs 2026-01-14Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Amy Burroughs 2026-01-14Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Andrew Gengos 2026-01-14Form 42026-01-160001563623-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Andrew Gengos 2026-01-14Form 42026-01-160001563623-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Emil Kuriakose 2026-01-14Form 42026-01-160001892413-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Emil Kuriakose 2026-01-14Form 42026-01-160001892413-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Amy Burroughs 2026-01-15Form 42026-01-160001872564-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, David Fellows 2026-02-01Form 42026-02-020001041126-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Jeffrey Kindler 2026-02-01Form 42026-02-020001174454-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Jill Quigley 2026-02-01Form 42026-02-020001799780-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Robert Azelby 2026-02-01Form 42026-02-020001656998-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Radhika Tripuraneni 2026-02-01Form 42026-02-020001761114-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Heather Turner 2026-02-01Form 42026-02-020001403571-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Amy Burroughs 2026-02-17Form 42026-02-180001872564-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Amy Burroughs 2026-02-17Form 42026-02-180001872564-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Amy Burroughs 2026-02-17Form 42026-02-180001872564-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Amy Burroughs 2026-02-17Form 42026-02-180001872564-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Amy Burroughs 2026-02-17Form 42026-02-180001872564-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Amy Burroughs 2026-03-16Form 42026-03-170001872564-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Amy Burroughs 2026-03-16Form 42026-03-170001872564-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Amy Burroughs 2026-03-16Form 42026-03-170001872564-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Amy Burroughs 2026-03-16Form 42026-03-170001872564-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Emil Kuriakose 2026-04-01Form 42026-04-020001892413-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Robert Azelby 2026-05-05Form 42026-05-050001656998-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Amy Burroughs 2026-05-05Form 42026-05-050001872564-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Amy Burroughs 2026-05-05Form 42026-05-050001872564-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Andrew Gengos 2026-05-05Form 42026-05-050001563623-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Heather Turner 2026-05-05Form 42026-05-050001403571-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Heather Turner 2026-05-05Form 42026-05-050001403571-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Amy Burroughs 2026-05-05Form 42026-05-050001872564-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Amy Burroughs 2026-05-05Form 42026-05-050001872564-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Amy Burroughs 2026-05-05Form 42026-05-050001872564-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Amy Burroughs 2026-05-05Form 42026-05-050001872564-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Andrew Gengos 2026-05-05Form 42026-05-050001563623-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Andrew Gengos 2026-05-05Form 42026-05-050001563623-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Andrew Gengos 2026-05-05Form 42026-05-050001563623-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Emil Kuriakose 2026-05-05Form 42026-05-050001892413-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, David Fellows 2026-05-05Form 42026-05-050001041126-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Jeffrey Kindler 2026-05-05Form 42026-05-050001174454-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Jill Quigley 2026-05-05Form 42026-05-050001799780-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Radhika Tripuraneni 2026-05-05Form 42026-05-050001761114-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Heather Turner 2026-05-05Form 42026-05-050001403571-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Robert Azelby 2026-05-05Form 42026-05-050001656998-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
126Section 06, 2025 voteForm 8-K2025-06-160000950170-25-086758Item 5.07 · say-on-pay result. As reported: —. Filing ↗
127Section 06, 2024 voteForm 8-K2024-06-120000950170-24-072462Item 5.07 · say-on-pay result. As reported: —. Filing ↗
128Section 06, 2023 voteForm 8-K2023-06-140000950170-23-027988Item 5.07 · say-on-pay result. As reported: —. Filing ↗
129Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
130Section 09b board cost (computed)Computed——Cash 262,003 + equity 0 + all other 101,643 = 363,646, summed across the director compensation table rows.machine: formula: Σ = 363,646
131Terns Pharmaceuticals, Inc. (subject), Section 10b CEO totalDEF 14A2025-04-290000950170-25-060138CEO total compensation as printed in Terns Pharmaceuticals, Inc.'s own proxy. As printed: 8,240,502. Filing ↗machine: r3 · c29 · span 385759–385768

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Terns Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
TERN Peer Teardown Report